Top

Published in:

01-06-2014 | Original Communication

Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis

Authors: Alon Abraham, Vivian E. Drory

Published in: Journal of Neurology | Issue 6/2014

Abstract

Uric acid (UA) is considered to be one of the most important antioxidants in the blood. While high UA levels are found in many disease states, low UA levels are reported in many neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS). Various studies showed consistently that ALS patients have lower serum UA levels than healthy individuals, more prominently in cases with bulbar onset and longer disease duration. A systematic search of PubMed was conducted to retrieve published studies on UA levels in ALS patients. A meta-analysis was performed on published studies comparing UA levels between ALS patients and controls. This meta-analysis revealed highly statistically significant (p < 0.0001) lower UA levels and a very large size effect in 311 ALS patients compared to 515 controls as a group, as well as calculated for men and women separately. Many studies indicate that patients with neurodegenerative diseases, including ALS, have low UA levels. Our meta-analysis strengthens these findings in ALS patients, demonstrating highly statistically significant (p < 0.0001) lower UA levels in patients compared to controls, with very large total size effect, more prominent in men.

Johnson RJ, Gaucher EA, Sautin YY, Henderson GN, Angerhofer AJ, Benner SA (2008) The planetary biology of ascorbate and uric acid and their relationship with the epidemic of obesity and cardiovascular disease. Med Hypotheses 71:22–31PubMedCentralCrossRefPubMed

Ames BN, Cathcart R, Schwiers E, Hochstein P (1981) Uric acid provides an antioxidant defense in humans against oxidant and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78:6858–6862PubMedCentralCrossRefPubMed

Kutzing MK, Firestein BL (2008) Altered uric acid levels and disease states. J Pharmacol Exp Ther 324:1–7CrossRefPubMed

Alvarez-Lario B, Macarron-Vicente J (2011) Is there anything good in uric acid? QJM 104:1015–1024CrossRefPubMed

Pak CY, Moe OW, Sakhaee K, Peterson RD, Poindexter JR (2005) Physicochemical metabolic characteristics for calcium oxalate stone formation in patients with gouty diathesis. J Urol 173:1606–1609CrossRefPubMed

Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH (2009) Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum 61:225–232CrossRefPubMed

Scott GS, Hooper DC (2001) The role of uric acid in protection against peroxynitrite-mediated pathology. Med Hypotheses 56:95–100CrossRefPubMed

Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, Lee SJ, Lee C, Paik IH, Lee CU (2006) Decreased plasma antioxidants in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 21:344–348CrossRefPubMed

Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Peterson RC, Ascherio A, Aisen PS (2009) Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 6:23–28CrossRef

10.

Euser SM, Hofman A, Westendorp RG, Breteler MM (2009) Serum uric acid and cognitive function and dementia. Brain 132:377–382CrossRefPubMed

11.

Andreadou E, Nikolaou C, Gournaras F, Rentzos M, Boufidou F, Tsoutsou A, Zournas C, Zissimopoulos V, Vassilopoulos D (2009) Serum uric acid levels in patients with Parkinson’s disease: their relationship to treatment and disease duration. Clin Neurol Neurosurg 111:724–728CrossRefPubMed

12.

Chen H, Mosley TH, Alonso A, Huang X (2009) Plasma urate and Parkinson’s disease in the atherosclerosis risk in communities (ARIC) study. Am J Epidemiol 169:1064–1069PubMedCentralCrossRefPubMed

13.

Winquist A, Steenland K, Shankar A (2010) Higher serum uric acid associated with decreased Parkinson’s disease prevalence in a large community-based survey. Mov Disord 25:932–936CrossRefPubMed

14.

de Lau LM, Koudstaal PJ, Hofman A, Breteler MM (2005) Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58:797–800CrossRefPubMed

15.

Weisskopf MG, O’Reilly E, Chen H, Schwarzschild MA, Ascherio A (2007) Plasma urate and risk of Parkinson’s disease. Am J Epidemiol 166:561–567PubMedCentralCrossRefPubMed

16.

O’Reilly EJ, Gao X, Weisskopf MG, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A (2010) Plasma urate and Parkinson’s disease in women. Am J Epidemiol 172:666–670PubMedCentralCrossRefPubMed

17.

Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM (1996) Observations on serum uric acid levels and the risk of idiopathic Parkinson’s disease. Am J Epidemiol 144:480–484CrossRefPubMed

18.

Lee JE, Song SK, Sohn YH, Lee PH (2011) Uric acid as a potential disease modifier in patients with multiple system atrophy. Mov Disord 26:1533–1536CrossRefPubMed

19.

Auinger P, Kieburtz K, McDermott MP (2010) The relationship between uric acid levels and Huntington’s disease progression. Mov Disord 25:224–228PubMedCentralCrossRefPubMed

20.

Rentzos M, Nikolaou C, Anagnostouli M, Rombos A, Tsakanikas K, Economou M, Dimitrakopoulos A, Karouli M, Vassilopoulos D (2006) Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg 108:527–531CrossRefPubMed

21.

Toncev G, Milicic B, Toncev S, Samardzic G (2002) Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 9:221–226CrossRefPubMed

22.

Guerrero AL, Martin-Polo J, Laherran E, Gutierrez F, Iglesias F, Tejero MA, Rodriguez-Gallego M, Alcazar C (2008) Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment. Eur J Neurol 15:394–397CrossRefPubMed

23.

Zoccolella S, Simone IL, Capozzo R, Tortelli R, Leo A, D’Errico E, Logroscino G (2011) An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis. J Neurol 258:238–243CrossRefPubMed

24.

Keizman D, Ish-Shalom M, Berliner S, Maimon N, Vered Y, Artamonov I, Tsehori J, Nefussy B, Drory VE (2009) Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci 285:95–99CrossRefPubMed

25.

Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y (2012) Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med 51:1501–1508CrossRefPubMed

26.

Paganoni S, Zhang M, Quiroz Zarate A, Jaffa M, Yu H, Cudkowicz ME, Wills AM (2012) Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol 259:1923–1928PubMedCentralCrossRefPubMed

27.

Kataoka H, Kiriyama T, Kobayashi Y, Horikawa H, Ueno S (2013) Clinical outcomes and serum uric acid levels in elderly patients with amyotrophic lateral sclerosis aged ≥70 years. Am J Neurodegener Dis 2:140–144PubMedCentralPubMed

28.

Zoccolella S, Palagano G, Fraddosio A, Russo I, Ferrannini E, Serlenga L, Maggio F, Lamberti S, Iliceto G (2002) ALS-plus: 5 cases of concomitant amyotrophic lateral sclerosis and parkinsonism. Neurol Sci 23(Suppl 2):S123–S124CrossRefPubMed

29.

Du Y, Chen CP, Tseng CY, Eisenberg Y, Firestein BL (2007) Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 55:463–472CrossRefPubMed

30.

Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80:4546–4550PubMedCentralCrossRefPubMed

31.

Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA (2012) Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson’s disease. PLoS One 7:e37331PubMedCentralCrossRefPubMed

32.

Gersch C, Palii SP, Imaram W, Kim KM, Karumanchi SA, Angerhofer A, Johnson RJ, Henderson GN (2009) Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. Nucleosides Nucleotides Nucleic Acids 28:118–149PubMedCentralCrossRefPubMed

33.

Santos CX, Anjos EI, Augusto O (1999) Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Biophys 372:285–294CrossRefPubMed

34.

Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, Koprowski H (1998) Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 95:675–680PubMedCentralCrossRefPubMed

35.

Kean RB, Spitsin SV, Mikheeva T, Scott GS, Hooper DC (2000) The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood–central nervous system barrier integrity. J Immunol 165:6511–6518CrossRefPubMed

36.

Drulovic J, Dujmovic I, Stojsavljevic N, Mesaros S, Andjelkovic S, Miljkovic D, Peric V, Dragutinovic G, Marinkovic J, Levic Z, Mostarica Stojkovic M (2001) Uric acid levels in sera from patients with multiple sclerosis. J Neurol 248:121–126CrossRefPubMed

37.

Alvarez-Lario B, Macarron-Vicente J (2010) Uric acid and evolution. Rheumatology (Oxford) 49:2010–2015CrossRef

38.

Gonsette RE, Sindic C, D’Hooghe MB, De Deyn PP, Medaer R, Michotte A, Seeldrayers P, Guillaume D (2010) Boosting endogenous neuroprotection in multiple sclerosis: the association of inosine and interferon beta in relapsing–remitting multiple sclerosis (ASIIMS) trial. Mult Scler 16:455–462CrossRefPubMed

39.

Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, de Antonelle Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K (2013) Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 71(2):141–150

Title: Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis
Authors: Alon Abraham
Vivian E. Drory
Publication date: 01-06-2014
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 6/2014
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-014-7331-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2014

Primitive reflexes in amyotrophic lateral sclerosis: prevalence and correlates

Transient and permanent neuroimaging abnormalities due to partial status epilepticus in a patient with corpus callosum agenesis

Increased α-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study

Risk factors for mortality in 600 patients in vegetative and minimally conscious states

An unusual cause of acute paraplegia in a 16-year-old dancer